Samsung BioLogics wants to reproduce the success of Samsung's semiconductor business in the bio market. As the world's largest manufacturer of biologics contracts, the company's sales and operating profit are expected to reach $1.7 billion and $850 million in 2020, respectively.
On December 21, Samsung Biopharmaceuticals announced that its third plant in the Incheon Free Economic Zone (Songdo) in South Korea broke ground. CEO TH Kim announced the relevant strategy and business status. By the fourth quarter of 2018, it will invest 723 million US dollars to start global operations. By then, the plant will produce 180,000 liters of liquid medicine per day, making it the largest in the world. The first and second plants were completed in 2013 and 2015 respectively.
Samsung Biopharmaceuticals operates the biopharmaceutical industry in the same way that Samsung Electronics operates the semiconductor business. Samsung Electronics has established a state-of-the-art semiconductor manufacturing facility and secured a global production base. Global semiconductor companies have commissioned Samsung Electronics to manufacture and develop Samsung Electronics as a global semiconductor business leader.
Beginning in 2020, the demand for biopharmaceuticals will rise to a certain level. Samsung Biopharmaceuticals will attract 70% of its own pharmaceutical companies to its customers with good reputation, stable productivity and competitive prices. (Text / Yalin translation)
Surgical Gown,Sterile Surgical Gown,Surgical Isolation Gown,Sms Disposable Surgical Gowns
ShaoXing SurgeCare Medical Products Co., Ltd. , https://www.sxsurgecaremedical.com